A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the efficacy and safety of 4 doses of BI
1744 CL inhalation solution delivered by the Respimat® inhaler once daily for four weeks in
patients with asthma in comparison to placebo.